Profit outpacing revenue
Profit grew 46.7% while revenue grew 7.4%, so the company kept more of each rupee of revenue as profit.
Importance 72 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Profit grew 46.7% while revenue grew 7.4%, so the company kept more of each rupee of revenue as profit.
Importance 72 / 95 · growth
P/E of 32.58× is below the chemicals and petrochemicals median (60.58×) — but ROE of 13.8% is also below that peer set (23.5%), so the lower multiple tracks the lower profitability.
Importance 58 / 95 · valuation
Profit has swung sharply over 7 years (from ₹642 to ₹2,162) — one year is a weak guide to the earnings power.
Importance 57 / 95 · growth
Net worth compounded at 19.1% a year over 7 years (₹4,129 → ₹14,043).
Importance 57 / 95 · financial health
Classified by the exchange under Commodities › Chemicals › Chemicals & Petrochemicals › Commodity Chemicals.
Peer set used on this page: 3 chemicals & petrochemicals.
Revenue grew 9.8% a year over 7 years, from ₹6,459 cr in FY2019 to ₹12,421 cr in FY2026. Net profit grew 18.8% a year over the same period.
Profit grew 46.7% while revenue grew 7.4%, so the company kept more of each rupee of revenue as profit.
Rule PROFIT_FASTER_THAN_REVENUE
Profit has swung sharply over 7 years (from ₹642 to ₹2,162) — one year is a weak guide to the earnings power.
Over 7 years profit compounded at 16.2% a year while revenue compounded at 10.8% a year — though FY2020 saw a one-off step-change of 59% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Net profit grew 46.7% year on year (FY2025 → FY2026).
Revenue has compounded at 10.8% a year over 7 years (₹7,693 → ₹15,787) — though FY2022 saw a one-off step-change of 48% (a merger, restructuring or a recovery off a low base), so the compounding is uneven — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,904 cr (up 34.7% on the same quarter last year) and net profit ₹509 cr (up 31.2%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 revenue was ₹4,904 cr, up 34.7% from ₹3,640 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 net profit was ₹509 cr, up 31.2% from ₹388 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 EBIT was ₹742 cr, up 26.2% from ₹588 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 3,491 | +14.4% | 271 | +7.0% | 7.8% |
| Q4 FY25 | 4,313 | +20.8% | 526 | +24.6% | 12.2% |
| Q1 FY26 | 3,819 | +10.2% | 432 | +71.4% | 11.3% |
| Q2 FY26 | 3,640 | +6.3% | 388 | +92.7% | 10.7% |
| Q3 FY26 | 3,713 | +6.3% | 433 | +59.6% | 11.7% |
| Q4 FY26 | 4,615 | +7.0% | 582 | +10.6% | 12.6% |
| Q1 FY27 | 5,033 | +31.8% | 759 | +75.5% | 15.1% |
| Q2 FY27 | 4,904 | +34.7% | 509 | +31.2% | 10.4% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 25.4% in FY2026, against 18.5% in FY2019. ROE was 14.2% and ROCE 16.0% in FY2026.
ROE of 13.8% is below the chemicals and petrochemicals median of 23.5%.
Rule ROE_BELOW_PEER_MEDIAN
ROE improved from 10.4% to 13.8% year on year.
EBITDA margin improved from 19.4% to 22.3% of revenue.
EBITDA margin has ranged from 18.1% to 26.2% over 7 years and sits at 22.3% now.
Debt-to-equity was 0.26x in FY2026, against 0.70x in FY2019; interest coverage 11.98x. Operating cash flow was 1.36x net profit.
Net worth compounded at 19.1% a year over 7 years (₹4,129 → ₹14,043).
Rule NET_WORTH_COMPOUNDING
Operating cash flow has matched or exceeded reported profit in 6 of the last 6 profit-making years (latest 1.39×).
Free cash flow has been positive in 5 of the last 6 years.
Within its 3-company Chemicals & Petrochemicals peer group, it ranks 3 of 3 on return on equity and 3 of 3 on EBITDA margin. Its P/E of 32.6 compares with a peer median of 60.6.
Ranked against 3 chemicals & petrochemicals (FY2026, consolidated).
SRF · 3rd of 3 · set median 11.1%
SRF · 3rd of 3 · set median 25.9%
SRF · 3rd of 3 · set median 23.5%
SRF · 1st of 3 · set median 60.6×
P/E of 32.58× is below the chemicals and petrochemicals median (60.58×) — but ROE of 13.8% is also below that peer set (23.5%), so the lower multiple tracks the lower profitability.
Rule CHEAP_VS_LOW_RETURNS
On the trailing twelve months. Last full year: P/E 40.5× · P/S 4.7× · ROE 13.8%. TTM and full-year profit and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is down 12.0% over 1 year, up 6.6% over 3 years (2.2% a year) and up 14.7% over 5 years (2.8% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 19.4% below its 52-week high.
Long-term price performance is shown above.
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6,459 | 6,331 | 6,988 | 9,953 | 12,074 | 10,787 | 11,698 | 12,421 |
| Total income | 6,502 | 6,382 | 7,052 | 10,017 | 12,180 | 10,906 | 11,873 | 12,549 |
| EBITDA | 1,196 | 1,316 | 1,805 | 2,669 | 3,300 | 2,509 | 2,631 | 3,152 |
| Profit before tax | 693 | 780 | 1,310 | 2,155 | 2,656 | 1,718 | 1,704 | 2,173 |
| Net profit | 517 | 974 | 925 | 1,507 | 2,023 | 1,374 | 1,268 | 1,725 |
| EPS (₹) | 90.0 | 169.5 | 158.7 | 50.9 | 68.3 | 46.4 | 42.8 | 58.2 |
| Net worth | 3,919 | 4,684 | 6,295 | 7,625 | 9,254 | 10,514 | 11,569 | 12,681 |
| Total debt | 2,738 | 1,922 | 2,185 | 2,775 | 3,039 | 3,612 | 3,253 | 3,313 |
| Operating cash flow | — | — | 1,422 | 1,638 | 2,788 | 1,903 | 2,264 | 2,346 |
| Free cash flow | — | — | 569 | 77 | 430 | 52 | 1,145 | 674 |
| Ratio | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||
| Revenue growth YoY | — | -2.0 | 10.4 | 42.4 | 21.3 | -10.7 | 8.4 | 6.2 |
| Profit growth YoY | — | 88.4 | -5.0 | 62.9 | 34.3 | -32.1 | -7.7 | 36.0 |
| Profitability | ||||||||
| EBITDA margin % | 18.5 | 20.8 | 25.8 | 26.8 | 27.3 | 23.3 | 22.5 | 25.4 |
| Net margin % | 8.0 | 15.3 | 13.1 | 15.0 | 16.6 | 12.6 | 10.7 | 13.7 |
| Return on equity % | 13.2 | 22.6 | 16.9 | 21.7 | 24.0 | 13.9 | 11.5 | 14.2 |
| Return on capital % | 13.0 | 14.5 | 18.8 | 23.8 | 25.0 | 14.8 | 13.8 | 16.0 |
| Leverage & cash | ||||||||
| Debt to equity | 0.70 | 0.41 | 0.35 | 0.36 | 0.33 | 0.34 | 0.28 | 0.26 |
| Cash flow ÷ profit | — | — | 1.54 | 1.09 | 1.38 | 1.38 | 1.79 | 1.36 |
| Current ratio | 1.03 | 0.95 | 1.43 | 1.35 | 1.44 | 1.23 | 1.42 | 1.31 |